The United States and United Kingdom Forge Duty-Free Arrangement on Prescription Drugs.
The UK and US have finalized a landmark commercial pact that will maintain zero import taxes on British drug exports entering the American market.
Key Provisions of the Pact
As part of the deal, the UK has committed to increase spending on medicines through the National Health Service (NHS). This pledge guarantees that duties on these key goods will remain at zero for a period of three years.
This deal follows earlier statements to hike duties on patented pharmaceutical products, with potential rates discussed as high as 100%.
"This agreement between the United Kingdom reinforces the worldwide climate for innovative medicines and establishes much-needed equity to transatlantic medicine commerce," an announcement noted.
Economic Importance
Drugs represent one of the UK's largest goods shipped to the United States, which is by far the biggest destination for leading companies like GSK and AstraZeneca.
Statistics indicate that in the 12 months to the end of the third quarter, the UK sold pharmaceutical products totaling over eleven billion pounds to the US. This value represented nearly one-fifth of all goods exports in that period.
"This agreement protects employment, stimulates investment and sets the stage for the UK to emerge as a global hub for biotech and pharma," a minister remarked.
Specific UK Commitments
The pact includes several notable commitments from the UK:
- Higher Cost Ceiling: The UK will increase the affordability limit at which it judges new treatments to be prohibitively costly by 25%.
- Higher Drug Budget: There is a goal to double overall health service expenditure on medicines from 0.3 percent of GDP to 0.6 percent over the next decade.
- Payback Limit: The amount manufacturers must return to the NHS to prevent overspending will be limited at fifteen percent. In the past, rebates exceeded twenty percent.
Broader Context
The pact comes amid a long-running dispute between the pharmaceutical industry and the ministers over spending levels and regulatory access.
These tensions were exacerbated by claims that American consumers were charged significantly more for the equivalent treatments than consumers in the Britain and the EU.
Recently, several significant drug company projects in the UK have been paused or cancelled, while multi-billion-dollar expansions have been directed toward American operations.
A senior figure acknowledged that the NHS must invest a greater share on treatments, noting that its expenditure on drugs had decreased as a share of its resources over the last ten years.
